The proportion of contemporary invasive pneumococcal disease and pneumococcal pneumonia in UK adults reflected by serotypes included in the 13-valent pneumococcal conjugate vaccine and next generation higher valency pneumococcal conjugate vaccines in development

• Published in: Vaccine Vol. 38; no. 51; pp. 8068 - 8070
• Main Authors: Vyse, Andrew, Campling, James, Czudek, Carole, Ellsbury, Gillian, Slack, Mary
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 03.12.2020; Elsevier Limited
• Subjects: Adult; Adults; Age; Asplenia; Conjugate; Conjugates; Disease; Distribution; Health risks; Humans; Immunization; Infant; Older people; Pneumococcal; Pneumococcal Infections - epidemiology; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines; Pneumonia; Pneumonia, Pneumococcal - epidemiology; Pneumonia, Pneumococcal - prevention & control; Polysaccharides; Serogroup; Serotype; Serotypes; Serotyping; Spleen; Surveillance; Trends; United Kingdom - epidemiology; Urban areas; Vaccine; Vaccines; Vaccines, Conjugate; Valency; United Kingdom; England; United Kingdom > UK; United States > US; Wales; Pneumococcal; Conjugate; Disease; Distribution; Adult; Vaccine; Serotype
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2020.10.090

At present all UK adults aged 65+ years and those considered at increased risk of pneumococcal infection are routinely offered a single dose of the 23-valent pneumococcal polysaccharide vaccine (PPV-23) with re-vaccination recommended for patients with chronic renal disease and asplenia/splenic dysfunction [1]. There is also a lack of consistent evidence showing PPV-23 effectiveness against adult community acquired pneumonia (CAP), which reflects a much larger disease burden compared to adult IPD with the pneumococcus an important cause [4]. Since 2013/14 there has been a rapid increase in IPD in older UK adults aged 65+ years that is especially attributed to several PPV-23 non PCV-13 (PPV-23non13) serotypes [2]. The second presents data from a prospective study of hospitalised CAP in adults aged 16+ years living in Greater Nottingham (a local region consisting of the city of Nottingham and the adjoining urban areas of Nottinghamshire and Derbyshire in the East Midlands of England) from 2013 to 2018 where the 24 pneumococcal serotypes included in PCV-13 and PPV-23 were individually identified from cases of pneumococcal CAP using a 24-valent multiplex urinary assay [7]. [...]directly vaccinating adults aged 65+ years with next generation higher valency PCVs may also be needed to optimally address the full vaccine preventable pneumococcal disease burden.